Tiger Brokers

  • Quotes
  • Products
    • Cash Boost Account
    • US Stocks
    • US Fractional Shares
    • HK Stocks
    • China A-shares
    • Options
    • Futures
    • US Treasury
    • Auto-invest
    • Fixed Coupon Notes
    • Tiger BOSS Debit Card
    • Fund Mall
    • Tiger Vault
    • Tiger Open Platform
    • Wealth
  • Pricing
    • Prime
      • Stocks & ETFs
      • Options, Warrants & CBBCs
      • Futures
      • Bonds
      • Fund Mall
    • Cash Boost
      • Stocks & ETFs
    • Financing Interest Rates
  • Promotions
  • Help
    • Account Operations
      • How to Open an Account?
      • Account Opening Documents
      • Account Types Available
    • Transfer & Pay
      • Account Funding
      • DDA Fast Deposit
      • Funds Withdrawal
      • Shares Transfer-in
      • Shares Transfer-out
      • Currency Conversion
    • Products & Trading
      • Products Available
      • Order Types
      • Trading Rules
      • Declaration
    • Margin Trading & Short Selling
      • Margin & Leverage
      • Risk Management
      • Short Selling Risk
    • Fund Mall
      • Open a fund account and transaction
    • Cash Boost Account
      • Cash Boost Account FAQ
      • How to Open Cash Boost Account
      • How to Contra Trade using Cash Boost Account
      • How to link your CDP Securities Account
    • Tiger Boss Debit Card
      • Frequently Asked Questions
      • Fees of the Debit card
      • How to Top-up
      • How to use my Debit card
    • Tiger Vault
      • Features of Tiger Vault
      • Transaction Fees
    • Statement
      • Statement
      • Dividends
  • Learn
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
  • Careers
    • L.E.A.P Programme
    • Investment Representative
    • Careers Portal
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immix Biopharma, Inc.

2.65
-0.0600-2.21%
Post-market: 2.650.00000.00%16:43 EDT
Volume:286.92K
Turnover:769.85K
Market Cap:73.81M
PE:-3.79
High:2.74
Open:2.70
Low:2.61
Close:2.71
Loading ...
OverviewCompanyNewsFilings

Immix Biopharma Inc. Unveils Presentation on Pioneering Cell Therapy for AL Amyloidosis and Other Serious Diseases

Reuters
·
03 May

Immix Biopharma’s Nxc-201 Nexicart-2 Clinical Trial Data Selected for Oral Presentation at Asco 2025

THOMSON REUTERS
·
23 Apr

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

GlobeNewswire
·
23 Apr

Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
26 Mar

Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy

MT Newswires Live
·
10 Feb

BRIEF-Immix Biopharma Receives FDA RMAT Designation For NXC-201

Reuters
·
10 Feb

Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis

TIPRANKS
·
10 Feb

Immix Biopharma Inc: Enrollment in Nexicart-2 Study Accelerating; Next Update Planned for H1 2025

THOMSON REUTERS
·
10 Feb

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Nxc-201, Sterically-Optimized CAR-T for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS
·
10 Feb

Several Insiders Invested In Immix Biopharma Flagging Positive News

Simply Wall St.
·
05 Feb

Analyst Rate

Buy
Buy
100.00%
Hold
0.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
May 08, 2025 Post Market
Financial Report Announcement
Mar 24, 2025 Post Market
Financial Report Announcement
Nov 12, 2024 Post Market
Financial Report Announcement
Aug 12, 2024 Post Market
Financial Report Announcement
May 09, 2024 Post Market

Dividend History

no data

No relevant data is available

Valuation Analysis

-3.67
Current
-4.35
Sector Average
29.57%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-3.67
Maximum
-0.45
+1 STD
1.20
Minimum
-32.22
-1 STD
-9.90
Average
-4.35

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Fintech (Singapore) Pte. Ltd.
Email Address:
uservice@ttm.financial
User Agreement|Privacy Policy

Copyright © Tiger Fintech (Singapore) Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.